Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms.
López-Torres
Enrique
E
Salomón
Jesús
J
Vicario
Francis
F
Peñas-Lledó
Eva
E
Dorado
Pedro
P
Llerena
Adrián
A
D000293:Adolescent; D000483:Alleles; D014150:Antipsychotic Agents / Q000627:therapeutic use / Q000633:toxicity*; D000068180:Aripiprazole; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D020734:Parkinsonian Disorders / Q000139:chemically induced* / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity*; D011110:Polymorphism, Genetic / Q000235:genetics*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000235:genetics*; D015363:Quinolones / Q000627:therapeutic use / Q000633:toxicity*; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics*; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012307:Risk Factors
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D000068180:Aripiprazole